$TELO
Telomir Pharmaceuticals, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Miami, FL
TELO chart
What traders are saying about $TELO
Latest postsTelomir Pharmaceuticals, Inc. news
- Telomir Pharmaceuticals, Inc. Estimates – NASDAQ:TELO
TradingView ·
- Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Yahoo Finance ·
- Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
Yahoo Finance ·
- Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Yahoo Finance ·
- Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Yahoo Finance ·
- Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Yahoo Finance ·
- Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
Yahoo Finance ·
- Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Yahoo Finance ·
- Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Yahoo Finance ·
- Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
Yahoo Finance ·
- Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
Yahoo Finance ·
- Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
Yahoo Finance ·
Telomir Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$10.4M | -$16.5M | -$13.1M | -$854,147 |
| Diluted EPS | $-0.33 | $-0.56 | $0.48 | $-0.03 |
| Total assets (year end) | $7.3M | $1.3M | $4.8M | $48,730 |
| Cash and equivalents (year end) | – | $1.3M | – | – |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Telomir Pharmaceuticals, Inc.
- Ticker
- TELO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Miami, FL
- Incorporated in
- FL
- Fiscal year end
- December 31
- SEC CIK
- 1971532
Frequently asked questions
What exchange is Telomir Pharmaceuticals, Inc. listed on?
Telomir Pharmaceuticals, Inc. trades on the Nasdaq under the ticker symbol TELO.
What industry is Telomir Pharmaceuticals, Inc. in?
Telomir Pharmaceuticals, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Telomir Pharmaceuticals, Inc. headquartered?
Telomir Pharmaceuticals, Inc.'s business address on file with the SEC is in Miami, FL.
When does Telomir Pharmaceuticals, Inc.'s fiscal year end?
Telomir Pharmaceuticals, Inc.'s fiscal year ends on December 31.